OMER vs. VNDA, NKTR, ZVRA, TRVI, OGI, CAPR, GALT, PBYI, IVA, and VERU
Should you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Vanda Pharmaceuticals (VNDA), Nektar Therapeutics (NKTR), Zevra Therapeutics (ZVRA), Trevi Therapeutics (TRVI), Organigram (OGI), Capricor Therapeutics (CAPR), Galectin Therapeutics (GALT), Puma Biotechnology (PBYI), Inventiva (IVA), and Veru (VERU). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.
Vanda Pharmaceuticals has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
Omeros has a net margin of 0.00% compared to Omeros' net margin of -2.75%. Omeros' return on equity of -0.90% beat Vanda Pharmaceuticals' return on equity.
Omeros received 207 more outperform votes than Vanda Pharmaceuticals when rated by MarketBeat users. Likewise, 71.66% of users gave Omeros an outperform vote while only 68.55% of users gave Vanda Pharmaceuticals an outperform vote.
Vanda Pharmaceuticals has higher revenue and earnings than Omeros. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 7.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Omeros. MarketBeat recorded 5 mentions for Vanda Pharmaceuticals and 3 mentions for Omeros. Omeros' average media sentiment score of 0.30 beat Vanda Pharmaceuticals' score of -0.01 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.
Summary
Vanda Pharmaceuticals beats Omeros on 8 of the 14 factors compared between the two stocks.
Get Omeros News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
